^
    Back
    Association details:
    Biomarker:AR F877L + AR T878A
    Cancer:Prostate Cancer
    Drug:Xtandi (enzalutamide) (Androgen receptor inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Mol Cancer Ther
    Title:

    The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide

    Excerpt:
    Our data show that enzalutamide is only a very weak partial agonist of the AR F877L, and a strong partial agonist of the double-mutant AR.
    DOI:
    10.1158/1535-7163.MCT-15-0892